Developer docs
API playgroundTry for free, no card

Search company profiles

argenx

Full company profile

uuid0000beg

Namestring
argenx
Legal namestring
argenx SE
Websiteurl
argenx.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

argenx is a global commercial-stage immunology company founded in 2008 and headquartered in Amsterdam, Netherlands, with primary R&D operations in Ghent, Belgium and US operations in Boston. The company's core technology is its neonatal Fc receptor (FcRn) blockade platform, anchored by efgartigimod, a human IgG1 antibody fragment that binds FcRn with high affinity to reduce pathogenic IgG autoantibodies. Efgartigimod is commercialized as VYVGART (intravenous) and VYVGART Hytrulo (subcutaneous, co-formulated with Halozyme's ENHANZE technology), initially approved for generalized myasthenia gravis in anti-AChR antibody positive adults and, as of May 2026, expanded to all adult gMG serotypes. Additional regulatory approvals include CIDP (FDA) and UK MHRA approval, with breakthrough therapy designation for immune-mediated necrotizing myopathy.

argenx generates revenue primarily through direct global product net sales of the VYVGART franchise, priced at approximately $870,000 per patient per year. The company operates an enterprise field sales motion, distributing through specialty pharmacy networks and direct provider relationships across the US, Europe, UK, Japan, China (via Zai Lab), and additional markets. FY2025 product net sales reached $4.2B (+90% YoY), with the company achieving first-year operating profitability of $1.1B and net income of $1.3B. The pipeline is expanding to 10 clinical-stage molecules by end of 2026, including empasiprubart (Phase 3 for CIDP/MMN), adimanebart (Phase 2 for SMA/CMS/ALS), and indication-expansion programs for efgartigimod in myositis, Graves' disease, ITP, systemic sclerosis, and ocular myasthenia gravis, supporting the company's Vision 2030 goal of 50,000 patients across 10 labeled indications.

Short descriptiontext

argenx is a global immunology company that commercializes VYVGART, the first approved FcRn blocker, treating patients with severe autoimmune diseases such as generalized myasthenia gravis and CIDP through direct sales to healthcare providers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autoimmune disease therapeutics, FcRn antibody blockers, biopharmaceutical products, immunology drug development, neurology specialty drugs
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / Immunology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1VYVGART Product Sales
TypeOne Time License
Description

argenx generates revenue primarily through global product net sales of VYVGART (efgartigimod alfa and VYVGART Hytrulo). VYVGART is approved for generalized myasthenia gravis in adult patients who are anti-AChR antibody positive, with recent label expansion to all adult gMG patients regardless of serotype. The company also generates product net sales from both the intravenous infusion and subcutaneous injection formulations.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations
Pricing details1 tier
1VYVGART for gMG - annual treatment cost
ModelOtherBilling cadenceAnnual
Notes

Estimated at approximately $870,000 per year based on market analysis; TD Cowen estimates the IMNM market at $17 billion in the US with 20,000 patients at $870,000 per year

in.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1VYVGART
Description

Brand name for argenx's approved FcRn blocker drug (efgartigimod) marketed for generalized myasthenia gravis and other autoimmune indications.

careers.argenx.com
Core offering1 text field

argenx develops, manufactures, and commercializes FcRn blocker antibody therapeutics for severe autoimmune diseases. Its commercial products are VYVGART (efgartigimod alfa-fcab), an intravenous FcRn blocker, and VYVGART Hytrulo, a subcutaneous co-formulation with hyaluronidase-qvfc, both approved for generalized myasthenia gravis with Hytrulo additionally approved for CIDP. The company sells these products directly to healthcare providers, hospitals, and specialty pharmacy networks globally, and is advancing a pipeline of additional autoimmune candidates including empasiprubart and adimanebart.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4.04-point improvement in MGII PRO ocular scores at Week 4 vs 1.99 for placebo (p=0.012)
+3 more records
Product overview1 text field

argenx is a global immunology company that commercializes the first approved neonatal Fc receptor (FcRn) blocker, VYVGART (efgartigimod alfa-fcab), and its subcutaneous formulation VYVGART Hytrulo. VYVGART is approved for generalized myasthenia gravis across all adult serotypes. The company is advancing a pipeline of autoimmune disease candidates including empasiprubart (Phase 3 for CIDP/MMN) and adimanebart (Phase 2 for SMA/CMS/ALS), with multiple indication expansion programs for VYVGART including myositis, Graves' disease, ITP, systemic sclerosis, and ocular myasthenia gravis.

Product and service4 records
1VYVGART (efgartigimod alfa-fcab)
CategoryBiopharmaceutical therapeutic - FcRn blocker
Description

Intravenous neonatal Fc receptor (FcRn) blocker antibody fragment that reduces pathogenic IgG antibodies. Approved for adult patients with generalized myasthenia gravis across all serotypes including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.

2VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
CategoryBiopharmaceutical therapeutic - subcutaneous FcRn blocker
Description

Subcutaneous formulation of efgartigimod co-formulated with Halozyme ENHANZE technology for easier administration via prefilled syringe. Approved for generalized myasthenia gravis across all adult serotypes and for chronic inflammatory demyelinating polyneuropathy (CIDP).

3Empasiprubart (ARGX-117)
CategoryPipeline product candidate - autoimmune neurology
Description

Investigational FcRn-targeting antibody candidate in Phase 3 development for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), part of argenx's strategy to expand its autoimmune franchise beyond efgartigimod.

4Adimanebart (ARGX-119)
CategoryPipeline product candidate - neuromuscular therapeutics
Description

Investigational antibody in Phase 2 development for spinal muscular atrophy (SMA), Phase 1 for congenital myasthenic syndromes (CMS), and a Phase 2a study for amyotrophic lateral sclerosis (ALS), targeting the neuromuscular junction.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeOthersAnnounced on2026-06-10
Description

Customer testimonial at Planisware's Exchange26 EMEA conference in Paris. argenx presented alongside ABB, Safran, Europol, Novo Nordisk, IBSA, and Expanscience on AI-driven innovations for project and portfolio management.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

MindWalk's antibody discovery work produced discovery-originated drug candidates for argenx among its over 20 programs in active Phase 1-3 clinical trials. MindWalk's platform includes proprietary wet-lab antibody discovery and the HYFT biological intelligence infrastructure.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration for development and commercialization of VYVGART in Greater China. Zai Lab reported $94.2 million in full-year VYVGART franchise revenue and continues to advance pipeline programs including povetacicept in IgA nephropathy.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Partnership for ENHANZE drug delivery technology enabling subcutaneous administration of VYVGART. Halozyme's ENHANZE technology enables subcutaneous injection of large volume biologics, supporting the VYVGART Hytrulo prefilled syringe formulation. VYVGART Hytrulo has exceeded expectations at $4.2 billion in total revenues according to Halozyme projections.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-01-01
Description

Strategic partnership for technology-enabled pharmacovigilance services, supporting argenx's global safety monitoring and regulatory compliance activities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

International consortium led by genOway and including argenx, Innate Pharma, and Vir Biotechnology developed the genO-hFcγR mouse model enabling more accurate prediction of therapeutic antibody efficacy and safety in humans. The model addresses species-specific discrepancies in Fcγ receptors that cause unreliable results in standard laboratory mice, helping rank antibody candidates and reduce expensive late-stage clinical failures.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sanofi is a global immunology leader anchored by Dupixent and is expanding its autoimmune and rare disease portfolio, competing with argenx for autoimmune market share and specialty pharmacy channels.

TypeBroad incumbent
Description

AstraZeneca, through its Alexion acquisition, holds a leading position in rare autoimmune and complement-mediated diseases (e.g., ravulizumab), positioning it as a broad incumbent competing for rare autoimmune patients and specialty channel access.

TypeRegional player
Description

Zai Lab is argenx's strategic partner commercializing VYVGART in Greater China, reporting $94.2M in franchise revenue; comparable as a regional commercializer of innovative autoimmune therapies in China.

TypeBroad incumbent
Description

AbbVie is a broad incumbent in autoimmune diseases with Humira, Skyrizi, and Rinvoq dominating immunology markets; argenx competes for the same prescriber base and patient pool across overlapping autoimmune conditions.

TypeBroad incumbent
Description

Vertex Pharmaceuticals was named Bank of America's other top biotech pick for 2026 alongside argenx and is a comparable mid-to-large cap commercial-stage biotech with concentrated franchise economics.

TypeDirect peer
Description

Immunovant is a clinical-stage biotech developing batoclimab (IMVT-1401), an FcRn blocker targeting autoimmune diseases including gMG and other indications, making it a direct mechanism competitor to argenx.

TypeDirect peer
Description

Johnson & Johnson is developing nipocalimab (acquired via Momenta), an FcRn blocker in late-stage trials across multiple autoimmune indications, directly competing with argenx's pipeline expansion strategy beyond gMG.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb maintains a substantial immunology franchise (Sotyktu, Zeposia) and competes for autoimmune market share and specialty care prescribers that drive VYVGART adoption.

TypeDirect peer
Description

UCB commercializes rozanolixizumab, an FcRn antagonist approved in the EU for generalized myasthenia gravis, making it the closest direct competitor to argenx's VYVGART in the same mechanism and indication.

TypeOthers
Description

Halozyme is the technology partner supplying ENHANZE drug delivery technology that enables argenx's VYVGART Hytrulo subcutaneous formulation; it is an enabling supplier whose commercial success is partially tied to argenx's franchise performance.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

argenx

Biopharmaceuticals / Immunology Therapeuticsargenx.com

argenx is a global immunology company that commercializes VYVGART, the first approved FcRn blocker, treating patients with severe autoimmune diseases such as generalized myasthenia gravis and CIDP through direct sales to healthcare providers worldwide.

What argenx does

argenx is a global commercial-stage immunology company founded in 2008 and headquartered in Amsterdam, Netherlands, with primary R&D operations in Ghent, Belgium and US operations in Boston. The company's core technology is its neonatal Fc receptor (FcRn) blockade platform, anchored by efgartigimod, a human IgG1 antibody fragment that binds FcRn with high affinity to reduce pathogenic IgG autoantibodies. Efgartigimod is commercialized as VYVGART (intravenous) and VYVGART Hytrulo (subcutaneous, co-formulated with Halozyme's ENHANZE technology), initially approved for generalized myasthenia gravis in anti-AChR antibody positive adults and, as of May 2026, expanded to all adult gMG serotypes. Additional regulatory approvals include CIDP (FDA) and UK MHRA approval, with breakthrough therapy designation for immune-mediated necrotizing myopathy.

argenx generates revenue primarily through direct global product net sales of the VYVGART franchise, priced at approximately $870,000 per patient per year. The company operates an enterprise field sales motion, distributing through specialty pharmacy networks and direct provider relationships across the US, Europe, UK, Japan, China (via Zai Lab), and additional markets. FY2025 product net sales reached $4.2B (+90% YoY), with the company achieving first-year operating profitability of $1.1B and net income of $1.3B. The pipeline is expanding to 10 clinical-stage molecules by end of 2026, including empasiprubart (Phase 3 for CIDP/MMN), adimanebart (Phase 2 for SMA/CMS/ALS), and indication-expansion programs for efgartigimod in myositis, Graves' disease, ITP, systemic sclerosis, and ocular myasthenia gravis, supporting the company's Vision 2030 goal of 50,000 patients across 10 labeled indications.

argenx firmographics

Firmographics
Name
argenx
Legal name
argenx SE
Website
https://argenx.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
argenx is a global immunology company that commercializes VYVGART, the first approved FcRn blocker, treating patients with severe autoimmune diseases such as generalized myasthenia gravis and CIDP through direct sales to healthcare providers worldwide.
Ownership category
akta.pro rank

argenx industry classification

Industry
Product category
Biopharmaceuticals / Immunology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Autoimmune disease therapeutics
  • FcRn antibody blockers
  • Biopharmaceutical products
  • Immunology drug development
  • Neurology specialty drugs

Where argenx is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices4 records

Markets served

argenx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations

Revenue model

  1. VYVGART Product Sales: argenx generates revenue primarily through global product net sales of VYVGART (efgartigimod alfa and VYVGART Hytrulo). VYVGART is approved for generalized myasthenia gravis in adult patients who are anti-AChR antibody positive, with recent label expansion to all adult gMG patients regardless of serotype. The company also generates product net sales from both the intravenous infusion and subcutaneous injection formulations.

Pricing tiers

ModelBillingPrice
OtherAnnualVYVGART for gMG - annual treatment cost

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

argenx product offering

Product offering

Core offering

argenx develops, manufactures, and commercializes FcRn blocker antibody therapeutics for severe autoimmune diseases. Its commercial products are VYVGART (efgartigimod alfa-fcab), an intravenous FcRn blocker, and VYVGART Hytrulo, a subcutaneous co-formulation with hyaluronidase-qvfc, both approved for generalized myasthenia gravis with Hytrulo additionally approved for CIDP. The company sells these products directly to healthcare providers, hospitals, and specialty pharmacy networks globally, and is advancing a pipeline of additional autoimmune candidates including empasiprubart and adimanebart.

Product overview

argenx is a global immunology company that commercializes the first approved neonatal Fc receptor (FcRn) blocker, VYVGART (efgartigimod alfa-fcab), and its subcutaneous formulation VYVGART Hytrulo. VYVGART is approved for generalized myasthenia gravis across all adult serotypes. The company is advancing a pipeline of autoimmune disease candidates including empasiprubart (Phase 3 for CIDP/MMN) and adimanebart (Phase 2 for SMA/CMS/ALS), with multiple indication expansion programs for VYVGART including myositis, Graves' disease, ITP, systemic sclerosis, and ocular myasthenia gravis.

Differentiator

Problem solved

Functional benefit

Brands

  • VYVGART: Brand name for argenx's approved FcRn blocker drug (efgartigimod) marketed for generalized myasthenia gravis and other autoimmune indications.

Products and services

  • VYVGART (efgartigimod alfa-fcab) Intravenous neonatal Fc receptor (FcRn) blocker antibody fragment that reduces pathogenic IgG antibodies. Approved for adult patients with generalized myasthenia gravis across all serotypes including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.
  • VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous formulation of efgartigimod co-formulated with Halozyme ENHANZE technology for easier administration via prefilled syringe. Approved for generalized myasthenia gravis across all adult serotypes and for chronic inflammatory demyelinating polyneuropathy (CIDP).
  • Empasiprubart (ARGX-117) Investigational FcRn-targeting antibody candidate in Phase 3 development for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), part of argenx's strategy to expand its autoimmune franchise beyond efgartigimod.
  • Adimanebart (ARGX-119) Investigational antibody in Phase 2 development for spinal muscular atrophy (SMA), Phase 1 for congenital myasthenic syndromes (CMS), and a Phase 2a study for amyotrophic lateral sclerosis (ALS), targeting the neuromuscular junction.

Quantifiable outcome

  • 4.04-point improvement in MGII PRO ocular scores at Week 4 vs 1.99 for placebo (p=0.012)
  • +3 more outcomes

Companies that use argenx

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

argenx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

argenx partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • PlaniswareminorOthers · 10 June 2026Customer testimonial at Planisware's Exchange26 EMEA conference in Paris. argenx presented alongside ABB, Safran, Europol, Novo Nordisk, IBSA, and Expanscience on AI-driven innovations for project and portfolio management.
  • MindWalk HoldingsminorStrategic or Co-development Partner · 18 May 2026MindWalk's antibody discovery work produced discovery-originated drug candidates for argenx among its over 20 programs in active Phase 1-3 clinical trials. MindWalk's platform includes proprietary wet-lab antibody discovery and the HYFT biological intelligence infrastructure.
  • Zai LabcoreStrategic or Co-development Partner · 1 January 2025Collaboration for development and commercialization of VYVGART in Greater China. Zai Lab reported $94.2 million in full-year VYVGART franchise revenue and continues to advance pipeline programs including povetacicept in IgA nephropathy.
  • Halozyme TherapeuticscoreTechnology or Integration · 1 January 2024Partnership for ENHANZE drug delivery technology enabling subcutaneous administration of VYVGART. Halozyme's ENHANZE technology enables subcutaneous injection of large volume biologics, supporting the VYVGART Hytrulo prefilled syringe formulation. VYVGART Hytrulo has exceeded expectations at $4.2 billion in total revenues according to Halozyme projections.
  • IQVIAminorImplementation/ SI/ Consulting Partner · 1 January 2024Strategic partnership for technology-enabled pharmacovigilance services, supporting argenx's global safety monitoring and regulatory compliance activities.
  • genOwaycoreStrategic or Co-development Partner · 1 January 2024International consortium led by genOway and including argenx, Innate Pharma, and Vir Biotechnology developed the genO-hFcγR mouse model enabling more accurate prediction of therapeutic antibody efficacy and safety in humans. The model addresses species-specific discrepancies in Fcγ receptors that cause unreliable results in standard laboratory mice, helping rank antibody candidates and reduce expensive late-stage clinical failures.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

argenx competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Sanofi is a global immunology leader anchored by Dupixent and is expanding its autoimmune and rare disease portfolio, competing with argenx for autoimmune market share and specialty pharmacy channels.
  • AstraZeneca: AstraZeneca, through its Alexion acquisition, holds a leading position in rare autoimmune and complement-mediated diseases (e.g., ravulizumab), positioning it as a broad incumbent competing for rare autoimmune patients and specialty channel access.
  • AbbVie: AbbVie is a broad incumbent in autoimmune diseases with Humira, Skyrizi, and Rinvoq dominating immunology markets; argenx competes for the same prescriber base and patient pool across overlapping autoimmune conditions.
  • Vertex Pharmaceuticals: Vertex Pharmaceuticals was named Bank of America's other top biotech pick for 2026 alongside argenx and is a comparable mid-to-large cap commercial-stage biotech with concentrated franchise economics.
  • Bristol-Myers Squibb: Bristol-Myers Squibb maintains a substantial immunology franchise (Sotyktu, Zeposia) and competes for autoimmune market share and specialty care prescribers that drive VYVGART adoption.

Regional players

  • Zai Lab: Zai Lab is argenx's strategic partner commercializing VYVGART in Greater China, reporting $94.2M in franchise revenue; comparable as a regional commercializer of innovative autoimmune therapies in China.

Direct peers

  • Immunovant: Immunovant is a clinical-stage biotech developing batoclimab (IMVT-1401), an FcRn blocker targeting autoimmune diseases including gMG and other indications, making it a direct mechanism competitor to argenx.
  • Johnson & Johnson: Johnson & Johnson is developing nipocalimab (acquired via Momenta), an FcRn blocker in late-stage trials across multiple autoimmune indications, directly competing with argenx's pipeline expansion strategy beyond gMG.
  • UCB: UCB commercializes rozanolixizumab, an FcRn antagonist approved in the EU for generalized myasthenia gravis, making it the closest direct competitor to argenx's VYVGART in the same mechanism and indication.

Others

  • Halozyme Therapeutics: Halozyme is the technology partner supplying ENHANZE drug delivery technology that enables argenx's VYVGART Hytrulo subcutaneous formulation; it is an enabling supplier whose commercial success is partially tied to argenx's franchise performance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

argenx social profiles

Digital presence

argenx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

argenx leadership team

Management profile

Number of profiles

Profiles4 records

argenx funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

argenx M&A and investment

M&A and investment

M&A3 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about argenx

What does argenx do?

argenx develops, manufactures, and commercializes FcRn blocker antibody therapeutics for severe autoimmune diseases. Its commercial products are VYVGART (efgartigimod alfa-fcab), an intravenous FcRn blocker, and VYVGART Hytrulo, a subcutaneous co-formulation with hyaluronidase-qvfc, both approved for generalized myasthenia gravis with Hytrulo additionally approved for CIDP. The company sells these products directly to healthcare providers, hospitals, and specialty pharmacy networks globally, and is advancing a pipeline of additional autoimmune candidates including empasiprubart and adimanebart.

Is argenx a public or private company?

argenx is a public company. It is classified as public and is currently operating.

When was argenx founded?

argenx was founded in 2008. It employs 1,001 to 5,000 people.

Where is argenx based?

argenx is headquartered in Boston, United States, in the North America region.

How does argenx make money?

One revenue line is on record: VYVGART Product Sales.

Who are argenx's main competitors?

Broad incumbents on record are Sanofi, AstraZeneca, AbbVie, Vertex Pharmaceuticals and Bristol-Myers Squibb. Zai Lab is listed as a regional player. Direct peers are Immunovant, Johnson & Johnson and UCB. Halozyme Therapeutics is listed as an others.

Does argenx have an API?

No public API is recorded for argenx.

What industry is argenx in?

argenx's product category is Biopharmaceuticals / Immunology Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooCradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of ArgenxCradle announced that argenx is expanding use of its AI-driven protein engineering platform across more scientists and antibody discovery programs. The platform has helped argenx optimize leads and generate new antibody candidates targeting multiple properties. The expanded access supports argenx's effort to translate immunology discoveries into antibody-based medicines.PR NewswireCradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenxCradle announced that argenx is expanding use of its AI-driven protein engineering platform across more scientists and antibody discovery programs. The platform has helped argenx optimize existing leads and generate new antibody candidates targeting multiple properties. The expanded access supports argenx's effort to translate immunology discoveries into antibody-based medicines.PR NewswireCradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenxCradle announced that argenx is expanding use of its AI-driven protein engineering platform across more scientists and antibody discovery programs. The platform has helped argenx optimize leads and generate new antibody candidates targeting multiple properties. The expansion supports argenx's effort to translate immunology discoveries into antibody-based medicines.TradingViewPiper Sandler maintains argenx at Overweight, raises price target to $1350 from $1215Piper Sandler maintained argenx at Overweight and raised its price target to $1350 from $1215, an 11.1% increase. The target implies an upside of 53.7% from the Nov 13 close of $878.40. Recent analyst price targets range from $1090 to $1336.BioSpaceDeaths, failed trials and other recent setbacks in the autoimmune spaceMultiple companies have paused or ended autoimmune drug programs after patient deaths or safety signals, including Novartis and Bristol Myers Squibb suspending CAR T trials. Argenx shuttered a Phase 3 study for Vyvgart Hytrulo in Sjögren's disease, and Artiva cut 94% of employees after two deaths. Pfizer also ended a mid-stage study for a CXCR5 therapy.Pulse 2.0Argenx: Up To $1.15 Billion Acquisition Of Unnatural Products To Expand Peptide Drug Discovery PlatformArgenx agreed to acquire Unnatural Products for up to $1.15 billion, paying $550 million upfront and up to $595 million in milestone payments. The deal expands Argenx's peptide discovery capabilities beyond antibodies, with the transaction expected to close by end of 2026.TradingViewBiotech Dealmaker: Early-Stage Platforms And Tools Draw Capital As Full Buyouts Remain On The Sidelines This WeekArgenx agreed to acquire Unnatural Products for $550 million upfront, up to $1.15 billion total. BioNTech bought a pediatric priority review voucher for $205 million, and Blackstone committed up to $1.5 billion to fund Pfizer's GLP-1 program. Charles River acquired Frontage's bioanalysis operations for about $470 million.Business & FinancialBiotech Dealmaker: Early-Stage Platforms And Tools Draw Capital As Full Buyouts Remain On The Sidelines This WeekArgenx agreed to acquire Unnatural Products for $550 million upfront, up to $1.15 billion total. BioNTech bought a pediatric priority review voucher for $205 million, and Blackstone committed up to $1.5 billion to fund Pfizer's GLP-1 program. Charles River acquired Frontage's bioanalysis operations for about $470 million.Startup Researcherargenx to Acquire Unnatural Products for Up to US$1.15 BillionArgenx agreed to acquire Unnatural Products for up to $1.15 billion, paying $550 million upfront and up to $595 million on milestones. The deal adds UNP's macrocyclic peptide platform to argenx's antibody engineering, with closing expected by year-end.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGXPomerantz LLP is investigating argenx SE for potential securities fraud, advising investors to contact the firm. The investigation follows argenx's October 8, 2026 decision to discontinue its Phase 3 UNITY study of efgartigimod for Sjögren's disease, which caused the stock to fall 11.83% to $818.63.